Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.73 USD
−41.07 M USD
0.00 USD
43.59 M
About Galectin Therapeutics Inc.
Sector
Industry
CEO
Joel Lewis
Website
Headquarters
Norcross
Founded
2000
FIGI
BBG000BK6FP5
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of GALT is 2.78 USD — it has increased by 2.21% in the past 24 hours. Watch Galectin Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Galectin Therapeutics Inc. stocks are traded under the ticker GALT.
GALT stock has fallen by −0.71% compared to the previous week, the month change is a 6.11% rise, over the last year Galectin Therapeutics Inc. has showed a 42.56% increase.
We've gathered analysts' opinions on Galectin Therapeutics Inc. future price: according to them, GALT price has a max estimate of 11.00 USD and a min estimate of 11.00 USD. Watch GALT chart and read a more detailed Galectin Therapeutics Inc. stock forecast: see what analysts think of Galectin Therapeutics Inc. and suggest that you do with its stocks.
GALT reached its all-time high on Sep 12, 2003 with the price of 38.28 USD, and its all-time low was 0.30 USD and was reached on Jan 12, 2009. View more price dynamics on GALT chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GALT stock is 5.22% volatile and has beta coefficient of 1.57. Track Galectin Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Galectin Therapeutics Inc. there?
Today Galectin Therapeutics Inc. has the market capitalization of 174.48 M, it has decreased by −1.81% over the last week.
Yes, you can track Galectin Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Galectin Therapeutics Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
GALT earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.20 USD resulting in a 10.00% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about Galectin Therapeutics Inc. earnings.
GALT net income for the last quarter is −11.22 M USD, while the quarter before that showed −12.37 M USD of net income which accounts for 9.30% change. Track more Galectin Therapeutics Inc. financial stats to get the full picture.
No, GALT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 14.00 employees. See our rating of the largest employees — is Galectin Therapeutics Inc. on this list?
Like other stocks, GALT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Galectin Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Galectin Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Galectin Therapeutics Inc. stock shows the buy signal. See more of Galectin Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.